 Kimberley Bruce
Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Microglia | 5 | 2025 | 232 | 2.500 |
Why?
| | Alzheimer Disease | 3 | 2025 | 514 | 1.360 |
Why?
| | Muromegalovirus | 7 | 2022 | 21 | 1.190 |
Why?
| | Brain | 5 | 2025 | 2673 | 1.170 |
Why?
| | Fatty Liver | 4 | 2018 | 230 | 1.150 |
Why?
| | Lipoprotein Lipase | 4 | 2022 | 59 | 1.000 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2019 | 260 | 0.960 |
Why?
| | Fructose | 1 | 2025 | 106 | 0.910 |
Why?
| | Prenatal Exposure Delayed Effects | 6 | 2019 | 574 | 0.890 |
Why?
| | Lipid Metabolism | 3 | 2022 | 503 | 0.860 |
Why?
| | Herpesviridae Infections | 6 | 2024 | 141 | 0.830 |
Why?
| | Lipoproteins | 2 | 2023 | 172 | 0.830 |
Why?
| | Metabolic Syndrome | 3 | 2011 | 340 | 0.790 |
Why?
| | Fatty Acids | 2 | 2022 | 427 | 0.780 |
Why?
| | Neuroglia | 1 | 2022 | 163 | 0.730 |
Why?
| | Optical Imaging | 1 | 2021 | 56 | 0.720 |
Why?
| | Lipid Droplets | 1 | 2021 | 22 | 0.710 |
Why?
| | Glucose Intolerance | 1 | 2022 | 142 | 0.700 |
Why?
| | Neurodegenerative Diseases | 2 | 2021 | 113 | 0.700 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 430 | 0.670 |
Why?
| | DNA Methylation | 2 | 2023 | 611 | 0.660 |
Why?
| | Circadian Clocks | 4 | 2019 | 45 | 0.650 |
Why?
| | Diet, High-Fat | 8 | 2019 | 239 | 0.610 |
Why?
| | Neurons | 3 | 2022 | 1494 | 0.600 |
Why?
| | Animals | 33 | 2025 | 35391 | 0.540 |
Why?
| | Genes, Essential | 4 | 2014 | 22 | 0.540 |
Why?
| | CLOCK Proteins | 1 | 2016 | 6 | 0.520 |
Why?
| | Disease Models, Animal | 8 | 2024 | 4078 | 0.510 |
Why?
| | Sirtuin 1 | 1 | 2016 | 30 | 0.510 |
Why?
| | Membrane Glycoproteins | 3 | 2025 | 477 | 0.510 |
Why?
| | Disease Susceptibility | 1 | 2018 | 334 | 0.500 |
Why?
| | Mice | 26 | 2024 | 16961 | 0.500 |
Why?
| | Maternal Nutritional Physiological Phenomena | 4 | 2014 | 169 | 0.490 |
Why?
| | Sirtuin 3 | 1 | 2016 | 58 | 0.480 |
Why?
| | Nutritional Physiological Phenomena | 2 | 2012 | 53 | 0.470 |
Why?
| | Cytomegalovirus Infections | 3 | 2022 | 189 | 0.470 |
Why?
| | Dietary Fats | 3 | 2016 | 301 | 0.460 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 640 | 0.460 |
Why?
| | Receptors, Immunologic | 2 | 2025 | 217 | 0.410 |
Why?
| | 14-3-3 Proteins | 1 | 2012 | 18 | 0.390 |
Why?
| | Mice, Inbred C57BL | 12 | 2024 | 5455 | 0.390 |
Why?
| | Viral Proteins | 3 | 2024 | 327 | 0.360 |
Why?
| | Lipogenesis | 2 | 2009 | 59 | 0.340 |
Why?
| | Liver | 3 | 2016 | 1842 | 0.340 |
Why?
| | Mitochondria, Liver | 1 | 2009 | 74 | 0.320 |
Why?
| | Epigenesis, Genetic | 2 | 2011 | 617 | 0.320 |
Why?
| | Dendritic Cells | 3 | 2021 | 481 | 0.310 |
Why?
| | Olfactory Mucosa | 3 | 2024 | 64 | 0.280 |
Why?
| | Suprachiasmatic Nucleus | 2 | 2019 | 15 | 0.280 |
Why?
| | Virus Replication | 2 | 2021 | 452 | 0.280 |
Why?
| | Virus Internalization | 3 | 2021 | 47 | 0.270 |
Why?
| | Gene Expression Regulation | 5 | 2021 | 2542 | 0.270 |
Why?
| | Rhadinovirus | 2 | 2024 | 20 | 0.270 |
Why?
| | Pregnancy | 9 | 2019 | 6417 | 0.270 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2024 | 1058 | 0.270 |
Why?
| | Salivary Glands | 3 | 2021 | 29 | 0.260 |
Why?
| | Energy Metabolism | 1 | 2012 | 875 | 0.260 |
Why?
| | Triglycerides | 3 | 2023 | 528 | 0.250 |
Why?
| | Apolipoprotein E4 | 1 | 2025 | 34 | 0.230 |
Why?
| | Trigeminal Ganglion | 1 | 2024 | 25 | 0.230 |
Why?
| | Humans | 22 | 2025 | 129625 | 0.230 |
Why?
| | Receptors, Interferon | 1 | 2024 | 50 | 0.220 |
Why?
| | Herpes Simplex | 1 | 2024 | 92 | 0.220 |
Why?
| | Herpesvirus 1, Human | 1 | 2024 | 86 | 0.210 |
Why?
| | Interferon-gamma | 2 | 2024 | 772 | 0.210 |
Why?
| | Phenotype | 4 | 2021 | 3075 | 0.210 |
Why?
| | Circadian Rhythm | 3 | 2016 | 413 | 0.200 |
Why?
| | Lipodystrophy | 1 | 2022 | 13 | 0.200 |
Why?
| | Hypertriglyceridemia | 1 | 2022 | 39 | 0.200 |
Why?
| | Gene Expression Profiling | 4 | 2021 | 1687 | 0.200 |
Why?
| | Diet | 3 | 2023 | 1213 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2024 | 129 | 0.190 |
Why?
| | Cytomegalovirus Vaccines | 1 | 2021 | 3 | 0.190 |
Why?
| | Superinfection | 1 | 2021 | 6 | 0.190 |
Why?
| | Acinar Cells | 1 | 2021 | 13 | 0.190 |
Why?
| | Herpesviridae | 1 | 2021 | 22 | 0.190 |
Why?
| | Tissue Adhesions | 2 | 2012 | 30 | 0.190 |
Why?
| | Chemokines, CC | 1 | 2021 | 33 | 0.180 |
Why?
| | Obesity | 4 | 2018 | 2882 | 0.180 |
Why?
| | Mice, Inbred BALB C | 5 | 2021 | 1250 | 0.180 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2021 | 15 | 0.180 |
Why?
| | Estrogens | 1 | 2024 | 347 | 0.180 |
Why?
| | Substrate Specificity | 1 | 2021 | 371 | 0.180 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 426 | 0.180 |
Why?
| | Herpesvirus 3, Human | 1 | 2024 | 331 | 0.180 |
Why?
| | Cytomegalovirus | 1 | 2021 | 154 | 0.170 |
Why?
| | Ultracentrifugation | 1 | 2020 | 48 | 0.170 |
Why?
| | Inflammation | 4 | 2021 | 2750 | 0.170 |
Why?
| | Recombination, Genetic | 1 | 2021 | 190 | 0.170 |
Why?
| | Female | 17 | 2024 | 68734 | 0.170 |
Why?
| | Cholesterol, LDL | 1 | 2022 | 358 | 0.170 |
Why?
| | Lipids | 2 | 2021 | 627 | 0.170 |
Why?
| | Positron-Emission Tomography | 1 | 2021 | 282 | 0.170 |
Why?
| | Cell Death | 1 | 2021 | 354 | 0.170 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 207 | 0.160 |
Why?
| | Tobramycin | 1 | 2019 | 51 | 0.160 |
Why?
| | Astrocytes | 1 | 2021 | 195 | 0.160 |
Why?
| | Exosomes | 1 | 2020 | 97 | 0.160 |
Why?
| | Hypothalamus | 2 | 2017 | 149 | 0.160 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2021 | 539 | 0.160 |
Why?
| | Phospholipids | 1 | 2021 | 216 | 0.160 |
Why?
| | Insulin Resistance | 2 | 2022 | 1167 | 0.160 |
Why?
| | Photoperiod | 2 | 2016 | 46 | 0.150 |
Why?
| | Cholesterol | 1 | 2021 | 412 | 0.150 |
Why?
| | Quinolines | 1 | 2019 | 156 | 0.150 |
Why?
| | Precision Medicine | 1 | 2022 | 387 | 0.150 |
Why?
| | Viral Envelope Proteins | 1 | 2019 | 81 | 0.150 |
Why?
| | Myeloid Cells | 1 | 2019 | 142 | 0.150 |
Why?
| | Cell Line | 2 | 2021 | 2784 | 0.140 |
Why?
| | Lymph Nodes | 2 | 2021 | 472 | 0.140 |
Why?
| | Pseudomonas aeruginosa | 1 | 2019 | 348 | 0.140 |
Why?
| | Pravastatin | 1 | 2017 | 40 | 0.130 |
Why?
| | Simvastatin | 1 | 2017 | 60 | 0.130 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2016 | 4 | 0.130 |
Why?
| | Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2016 | 3 | 0.130 |
Why?
| | Glucose | 2 | 2022 | 1002 | 0.130 |
Why?
| | Muscular Diseases | 1 | 2017 | 107 | 0.130 |
Why?
| | Sterol Regulatory Element Binding Protein 1 | 1 | 2016 | 57 | 0.130 |
Why?
| | Nanoparticles | 1 | 2020 | 375 | 0.130 |
Why?
| | Fibrosis | 1 | 2019 | 526 | 0.130 |
Why?
| | Hyperlipidemias | 1 | 2017 | 126 | 0.130 |
Why?
| | Maternal Exposure | 1 | 2018 | 177 | 0.130 |
Why?
| | Acidosis | 1 | 2017 | 89 | 0.120 |
Why?
| | Body Composition | 2 | 2017 | 649 | 0.120 |
Why?
| | Oxidation-Reduction | 2 | 2016 | 1028 | 0.120 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2014 | 13 | 0.110 |
Why?
| | Eating | 2 | 2019 | 368 | 0.110 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 17 | 0.110 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 217 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1088 | 0.110 |
Why?
| | Proteomics | 1 | 2020 | 1055 | 0.110 |
Why?
| | Fibroblasts | 1 | 2019 | 953 | 0.110 |
Why?
| | Aging | 1 | 2024 | 1778 | 0.110 |
Why?
| | Adiposity | 2 | 2016 | 504 | 0.110 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1685 | 0.110 |
Why?
| | Weight Gain | 1 | 2017 | 509 | 0.110 |
Why?
| | Lung | 3 | 2024 | 3938 | 0.100 |
Why?
| | Macrophages | 2 | 2024 | 1488 | 0.100 |
Why?
| | Repressor Proteins | 1 | 2016 | 406 | 0.100 |
Why?
| | Ovary | 1 | 2014 | 209 | 0.100 |
Why?
| | Virus Activation | 2 | 2024 | 88 | 0.100 |
Why?
| | Prenatal Nutritional Physiological Phenomena | 2 | 2009 | 59 | 0.100 |
Why?
| | Epithelial Cells | 1 | 2019 | 1075 | 0.100 |
Why?
| | Appetite | 1 | 2012 | 61 | 0.090 |
Why?
| | Actins | 1 | 2014 | 411 | 0.090 |
Why?
| | Endometrium | 1 | 2011 | 56 | 0.090 |
Why?
| | Epithelium | 1 | 2012 | 314 | 0.090 |
Why?
| | Nose | 2 | 2021 | 63 | 0.090 |
Why?
| | Liver Transplantation | 1 | 2019 | 833 | 0.090 |
Why?
| | Disease Progression | 1 | 2019 | 2627 | 0.090 |
Why?
| | Blood Vessels | 1 | 2012 | 187 | 0.090 |
Why?
| | Models, Biological | 3 | 2017 | 1724 | 0.090 |
Why?
| | Pelvic Pain | 1 | 2010 | 32 | 0.090 |
Why?
| | MicroRNAs | 2 | 2024 | 679 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 3394 | 0.080 |
Why?
| | Electron Transport | 1 | 2009 | 112 | 0.080 |
Why?
| | Hyaluronan Receptors | 1 | 2009 | 97 | 0.080 |
Why?
| | Adipokines | 1 | 2009 | 47 | 0.080 |
Why?
| | Male | 9 | 2024 | 63670 | 0.080 |
Why?
| | Intra-Abdominal Fat | 1 | 2009 | 88 | 0.080 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2011 | 164 | 0.080 |
Why?
| | Lactation | 1 | 2009 | 175 | 0.070 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2012 | 824 | 0.070 |
Why?
| | Genetic Variation | 1 | 2012 | 939 | 0.070 |
Why?
| | Signal Transduction | 2 | 2021 | 4931 | 0.070 |
Why?
| | Feeding Behavior | 1 | 2012 | 622 | 0.070 |
Why?
| | Body Weight | 3 | 2017 | 940 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1035 | 0.070 |
Why?
| | Oxidative Stress | 2 | 2009 | 1266 | 0.060 |
Why?
| | Histones | 1 | 2011 | 589 | 0.060 |
Why?
| | Mice, Knockout | 3 | 2021 | 2881 | 0.060 |
Why?
| | Sleep | 1 | 2010 | 687 | 0.060 |
Why?
| | Aged | 1 | 2024 | 22061 | 0.060 |
Why?
| | Varicella Zoster Virus Infection | 1 | 2024 | 25 | 0.060 |
Why?
| | CD11c Antigen | 1 | 2024 | 41 | 0.060 |
Why?
| | Virus Latency | 1 | 2024 | 84 | 0.050 |
Why?
| | Gene Expression | 3 | 2014 | 1465 | 0.050 |
Why?
| | Sensory Receptor Cells | 1 | 2024 | 103 | 0.050 |
Why?
| | Molecular Dynamics Simulation | 1 | 2025 | 217 | 0.050 |
Why?
| | Alveolar Epithelial Cells | 1 | 2024 | 107 | 0.050 |
Why?
| | Apolipoprotein C-III | 1 | 2022 | 13 | 0.050 |
Why?
| | Central Nervous System | 1 | 2024 | 255 | 0.050 |
Why?
| | Middle Aged | 1 | 2024 | 31136 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2024 | 363 | 0.050 |
Why?
| | Oligonucleotides, Antisense | 1 | 2022 | 113 | 0.050 |
Why?
| | Protein Conformation | 1 | 2025 | 863 | 0.050 |
Why?
| | Phospholipase C beta | 1 | 2021 | 30 | 0.050 |
Why?
| | GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2021 | 18 | 0.050 |
Why?
| | Neurotoxins | 1 | 2021 | 28 | 0.050 |
Why?
| | Culture Media, Conditioned | 1 | 2021 | 110 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2021 | 69 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2274 | 0.050 |
Why?
| | Gene Knockout Techniques | 1 | 2021 | 109 | 0.050 |
Why?
| | Receptors, Odorant | 1 | 2021 | 39 | 0.050 |
Why?
| | Open Reading Frames | 1 | 2021 | 117 | 0.040 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2021 | 141 | 0.040 |
Why?
| | Abdomen | 2 | 2012 | 118 | 0.040 |
Why?
| | Virion | 1 | 2021 | 83 | 0.040 |
Why?
| | Vaccines, Attenuated | 1 | 2021 | 125 | 0.040 |
Why?
| | Viremia | 1 | 2021 | 131 | 0.040 |
Why?
| | Chemical Precipitation | 1 | 2020 | 37 | 0.040 |
Why?
| | Mutation | 2 | 2021 | 3717 | 0.040 |
Why?
| | Herpes Zoster | 1 | 2024 | 317 | 0.040 |
Why?
| | Benzofurans | 1 | 2019 | 19 | 0.040 |
Why?
| | Animal Structures | 1 | 2019 | 9 | 0.040 |
Why?
| | Microbial Viability | 1 | 2019 | 83 | 0.040 |
Why?
| | Body Fluids | 1 | 2019 | 63 | 0.040 |
Why?
| | Disease Transmission, Infectious | 1 | 2019 | 55 | 0.040 |
Why?
| | Drug Synergism | 1 | 2019 | 370 | 0.040 |
Why?
| | Protein Binding | 1 | 2025 | 2124 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2019 | 348 | 0.040 |
Why?
| | Macrophages, Alveolar | 1 | 2021 | 389 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 855 | 0.040 |
Why?
| | Chylomicron Remnants | 1 | 2017 | 1 | 0.030 |
Why?
| | Risk Factors | 1 | 2011 | 9786 | 0.030 |
Why?
| | Calorimetry | 1 | 2017 | 66 | 0.030 |
Why?
| | Hydrolysis | 1 | 2017 | 186 | 0.030 |
Why?
| | Dependovirus | 1 | 2017 | 63 | 0.030 |
Why?
| | Ceramides | 1 | 2017 | 112 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2022 | 715 | 0.030 |
Why?
| | Calorimetry, Indirect | 1 | 2016 | 81 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2017 | 355 | 0.030 |
Why?
| | Green Fluorescent Proteins | 1 | 2017 | 388 | 0.030 |
Why?
| | Gene Deletion | 1 | 2017 | 382 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 805 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2011 | 0.030 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2015 | 25 | 0.030 |
Why?
| | Algorithms | 2 | 2012 | 1616 | 0.030 |
Why?
| | Time Factors | 2 | 2017 | 6555 | 0.030 |
Why?
| | Adult | 4 | 2022 | 35599 | 0.030 |
Why?
| | Organ Size | 1 | 2014 | 446 | 0.030 |
Why?
| | Homeostasis | 1 | 2017 | 605 | 0.030 |
Why?
| | Spleen | 1 | 2015 | 509 | 0.030 |
Why?
| | Vaccination | 1 | 2021 | 1347 | 0.030 |
Why?
| | Weaning | 1 | 2012 | 48 | 0.030 |
Why?
| | Peritoneum | 1 | 2012 | 41 | 0.020 |
Why?
| | Systole | 1 | 2012 | 191 | 0.020 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2012 | 57 | 0.020 |
Why?
| | DNA Topoisomerases, Type I | 1 | 2011 | 14 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2012 | 203 | 0.020 |
Why?
| | Reference Standards | 1 | 2012 | 176 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2014 | 835 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2017 | 2128 | 0.020 |
Why?
| | Femoral Artery | 1 | 2012 | 174 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2012 | 199 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2019 | 4084 | 0.020 |
Why?
| | Peritoneal Diseases | 1 | 2010 | 4 | 0.020 |
Why?
| | Menstrual Cycle | 1 | 2011 | 121 | 0.020 |
Why?
| | Femur | 1 | 2012 | 243 | 0.020 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2010 | 84 | 0.020 |
Why?
| | Intestinal Obstruction | 1 | 2010 | 49 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 338 | 0.020 |
Why?
| | Insulin-Like Growth Factor II | 1 | 2009 | 24 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1293 | 0.020 |
Why?
| | PPAR alpha | 1 | 2009 | 58 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2009 | 116 | 0.020 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2009 | 45 | 0.020 |
Why?
| | Vasodilation | 1 | 2012 | 476 | 0.020 |
Why?
| | Laparoscopy | 1 | 2012 | 450 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2012 | 895 | 0.020 |
Why?
| | Software | 1 | 2011 | 608 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 723 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 840 | 0.020 |
Why?
| | Blood Pressure | 1 | 2012 | 1736 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2010 | 1202 | 0.020 |
Why?
| | RNA | 1 | 2011 | 882 | 0.010 |
Why?
| | Chronic Disease | 1 | 2010 | 1720 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2011 | 3378 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2009 | 2708 | 0.010 |
Why?
| | Biomarkers | 1 | 2009 | 3968 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2009 | 2006 | 0.010 |
Why?
|
|
Bruce's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|